Meta description: This regulatory update reports on a Dutch trial evaluating modern therapy with an implantable cardioverter defibrillator for dilated cardiomyopathy and the uncertain impact on sudden cardiac death risk.
As of February 19, 2026, the ClinicalTrials.gov entry shows the DUTCH ICD study is not yet recruiting. The trial is organized by University Medical Center Groningen, Amsterdam University Medical Center, and Radboud University Medical Center. The study uses implantable cardioverter defibrillator therapy as the intervention in patients with dilated cardiomyopathy at risk of sudden cardiac death.
What changed in the DUTCH ICD trial status?
The record shows the trial is not yet recruiting and is led by three Dutch centers: University Medical Center Groningen, Amsterdam University Medical Center, and Radboud University Medical Center. The intervention listed is implantable cardioverter defibrillator implantation in patients with dilated cardiomyopathy who face risk of sudden cardiac death. The entry does not specify trial endpoints or primary outcomes in the available text. As of the date shown, this status informs stakeholders about the ongoing regulatory and clinical development surrounding ICD use in this condition.
Why this matters for regulators and clinicians?
The event highlights how contemporary medical therapy may influence the benefit profile of device based risk reduction strategies in dilated cardiomyopathy. Regulators will watch for robust safety data and clearly defined performance expectations before updating labeling or guidance. Clinicians will assess how future results could alter patient selection, timing of ICD implantation, and integration with modern heart failure regimens. The absence of reported endpoints means that conclusions remain speculative pending formal study findings.
What are safety and risk considerations at this stage?
At present the record emphasizes device based therapy as the focal intervention alongside standard medical care. Safety assessments will hinge on data generated during any formal trial enrollment and follow up. Until results are available there is no firm signal on residual risk or potential reduction in sudden cardiac death for this specific patient population.
How can clinicians access more information and participate?
Official information is posted on ClinicalTrials.gov under NCT07415642. Clinicians and institutions may review eligibility and enrollment details via the public record. Sponsors and sites include University Medical Center Groningen, Amsterdam University Medical Center, and Radboud University Medical Center. The entry notes Not yet recruiting at this time.
- 1. What is the DUTCH ICD trial about? The trial evaluates whether contemporary medical therapy combined with implantable defibrillator intervention changes the risk reduction for sudden cardiac death in patients with dilated cardiomyopathy.
- 2. What is the current recruitment status? The ClinicalTrials.gov entry shows Not yet recruiting as of the published date.
- 3. Where can official information be found? See the ClinicalTrials.gov link: https://clinicaltrials.gov/study/NCT07415642?term=medical+device.
Conclusion
The DUTCH ICD trial represents a regulatory relevant effort to align device based therapy with current medical practice in dilated cardiomyopathy. While current information shows no recruitment yet, regulators and clinicians should monitor the official record for updates on endpoints, safety data, and practical implications for patient care.
Disclaimer
This article provides information for professionals and is not legal advice. It reflects the source text and available public information at the time of publication. Individual regulatory decisions require formal review by competent authorities.
https://clinicaltrials.gov/study/NCT07415642?term=medical+device